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Background: Consumption of plant sterols and plant stanols reduces low-density lipoprotein cholesterol
(LDL-C) concentrations. At the same time, plasma plant sterol concentrations will increase after plant
sterol consumption, but decrease after plant stanol consumption. In contrast to plant stanols, plant
sterols can undergo oxidation and form oxyphytosterols. Findings from in vitro and animal studies
suggest that oxyphytosterols might be atherogenic.
Objective: The objective was to examine whether plant sterol and stanol consumption changes fasting
plasma oxyphytosterol concentrations.
Design: A randomized, double blind, cross-over study was performed inwhich 43 healthy subjects (18e70
years) consumed for 4 weeks a plant sterol-enriched (3.0 g/d of plant sterols), a plant stanol-enriched
(3.0 g/d of plant stanols), and a control margarine separated by wash-out periods of 4 weeks.
Oxyphytosterol concentrations were determined in BHT-enriched plasma via GCeMS.
Results: Compared to control, serum LDL-C concentrations were reduced after plant sterol (8.1%;
p < 0.001) and plant stanol consumption (7.8%; p < 0.001). Plant sterol consumption did not change
plasma oxyphytosterol concentrations. On the other hand, intake of the plant stanol margarine reduced
7b-OH-campesterol by 0.07 ng/mL (w14%; p < 0.01) and by 0.07 ng/mL (w15%; p < 0.01) compared with
the control and sterol margarines, respectively. When standardized for serum cholesterol, effects on
these oxyphytosterols were comparable. In addition, plant stanol intake reduced cholesterol-
standardized 7-keto-campesterol levels compared with plant sterol intake (p < 0.05).
Conclusions: Daily consumption of a plant sterol-enriched margarine does not increase oxyphytosterol
concentrations, while plant stanol consumption may reduce the concentrations of the oxidative plant
sterol metabolites 7b-OH-campesterol and 7-keto-campesterol. This trial is registered at clinicaltrials.gov
as NCT01559428.
 2013 Elsevier Ireland Ltd. Open access under the Elsevier OA license.1. Introduction
Plant sterols are structurally related to cholesterol and only the
side-chain conﬁguration at the C24 position differs. Thus, both
components consist of a steroid nucleus with a double bondBiology, NUTRIM School for
niversity Medical Center, PO





er the Elsevier OA license.present at C5eC6. This double bond is missing in plant stanols, the
hydrogenated form of plant sterols. Humans are unable to syn-
thesize plant sterols and stanols, which means that serum plant
sterols are by deﬁnition diet-derived. On average, serum sitosterol
concentrations range from 0.12 to 0.62 mg/dL and campesterol
concentrations from 0.27 to 1.08 mg/dL [1]. Serum plant stanol
concentrations are approximately 100 times lower and vary be-
tween 2 and 10 mg/dL in the normal population [2].
Although plant sterol and plant stanol ester-enriched products
lower serum low-density lipoprotein cholesterol (LDL-C) concen-
trations to the same extent at the recommended intake of
approximately 2.5 g/day, they have a different effect on serum plant
sterol concentrations; i.e. increased plant sterol consumption will
elevate serum plant sterol concentrations, while an increased plant
S. Baumgartner et al. / Atherosclerosis 227 (2013) 414e419 415stanol consumption will lower serum plant sterol concentrations
[3]. The relevance of increased serum plant sterol concentrations
relates in great detail to the ongoing debate whether plant sterol
concentrations are positively associated with cardiovascular dis-
ease (CVD) risk or not. The atherogenicity of increased plant sterol
concentrations was ﬁrst suggested after the identiﬁcation of the
rare autosomal-recessively inheritable sterol storage disease phy-
tosterolemia. These patients are characterized by extremely high
plant sterol concentrations ranging from 10 to 65 mg/dL and
a strong predisposition for premature coronary atherosclerosis
[4,5]. Moreover, some epidemiological studies have suggested that
also in the general population plasma plant sterol concentrations
are positively associated with an increased risk to develop CVD [6e
8]. Results are however far from conclusive, since there are also
numerous studies that did not show this association [9]. How these
inconsistencies between study outcomes can be explained is not
known. One possibility is that the potential association between
circulating plant sterols and CVD risk may not relate to plant sterols
per se, but to the fact that serum plant sterols are a marker for
intestinal cholesterol absorption [10]. In other words, it is possible
that an increased absorption of cholesterol associates with CVD risk
[11]. Alternatively, it is possible that oxidation of plant sterols e i.e.
the formation of oxyphytosterols e is important to explain the
potential association between plant sterol concentrations and CVD
risk. Like cholesterol, plant sterols can undergo oxidation, as they
possess a double bond between C5eC6 in the steroid nucleus
(Fig. 1). Ring-oxidation products of cholesterol may be atherogenic
[12e14], while not much is known about the biological effects of
ring-oxyphytosterols. Oxyphytosterols ﬁrst received attention as
potential mediators of CVD risk after it was shown that about 1.4%
of circulating sitosterol in serum of phytosterolemic patients was
present in its oxidized form [15]. Plant stanols do not have a double
bond in the steroid nucleus and can therefore not oxidize [16]. In
light of the widespread use of plant sterol-enriched products, it is
important to identify whether an increased intake of plant sterols
will result in increased plasma oxyphytosterol concentrations.
Another interesting question is whether an increased plant stanol
intake will not only decrease serum plant sterol concentrations, but
will also change those of the oxyphytosterols. Therefore, the
objective of this study was to examine the effects of consumingFig. 1. Non-enzymatically formed oxysitosterol structures. Similar strplant sterol or stanol ester-enriched margarines on fasting serum
oxyphytosterol concentrations in healthy volunteers.
2. Subjects and methods
2.1. Subjects
Subjects were recruited through announcements in local
newspapers and university buildings in Maastricht, the Nether-
lands, between February and April 2010. They were invited for two
screening visits if they met the following criteria: aged between 18
and 70 years, BMI between 20 and 30 kg/m2, no active car-
diovascular disease or severe medical condition that might inter-
fere with the study, no use of lipid-lowering medication or
a medically prescribed diet, stable body weight during the last
three months, and no consumption of plant sterol- or plant stanol-
enriched products in the previous month. During the screening
visits, weight and height were measured and two fasting blood
samples were drawn to determine plasma glucose and serum lipid
and lipoprotein concentrations. Forty-seven subjects (18 male and
29 female) were enrolled in the study. Two subjects did not
complete the study due to time constraints and difﬁculties per-
forming the venipuncture. In addition, two subjects were excluded
before the analyses of the results: one male subject was not fasted
during one blood sampling day and one female subject did not
comply with margarine consumption. Baseline characteristics are
shown in Table 1. All participants gave written informed consent
before entering the study. The protocol was approved by the
medical ethical committee of the Maastricht University Medical
Centreþ (MUMCþ). This trial is registered at clinicaltrials.gov as
NCT01559428.
2.2. Diet and design
Subjects participated in a randomized placebo-controlled cross-
over trial, which consisted of three intervention periods of 4 weeks,
separated by wash-out periods of 4 weeks. They were allocated to
the intervention periods in a randomized order, based upon
a computer-generated table with random numbers. During each
period, subjects were asked to replace their own spread with theuctures are also formed for campesterol and other plant sterols.
Table 1
Baseline characteristics of the subjects (n ¼ 43).
Age (years) 41  18
Male/Female (n) 17/26
BMI (kg/m2) 24.8  2.8
Weight (kg) 73.2  11.0
Height (m) 1.72  0.1
Glucose (mmol/L) 5.25  0.54
Total cholesterol (mmol/L) 5.72  1.12
LDL cholesterol (mmol/L) 3.53  1.06
HDL cholesterol (mmol/L) 1.69  0.37
Triacylglycerol (mmol/L) 1.14  0.46
Values are means  SD.
S. Baumgartner et al. / Atherosclerosis 227 (2013) 414e419416test margarine (70% fat) of which 20 g had to be consumed on
a daily basis. The daily intake of 20 g of margarine provided no, or
3.0 g of plant sterols or stanols per day, referred to as the control,
sterol or stanol condition. The margarines were packed in tubs of
140 g each, providing margarine for 7 days. The margarines were
similar in color and taste and the tubs were color coded to blind
both subjects and investigators. All volunteers received instructions
to consume the margarines divided over two meals, i.e. at lunch
and diner. The margarines were all rapeseed oil based with (satu-
rated) soysterols as the source of the plant sterols/stanols. Plant
sterols and stanols were provided as fatty acid esters by trans-
esteriﬁcation of free plant sterols and stanols with rapeseed oil
fatty acids. The plant sterol ester mixtures contained mainly
sitosterol ester (43%), campesterol ester (25%) and stigmasterol
ester (20%). Plant stanol mixtures were obtained by saturation of
these sterols, resulting in sitostanol ester (76%) and campestanol
ester (22%) (Raisio group, Raisio, Finland). Plant sterol, plant stanol
and oxyphytosterol content of the margarines are shown in Table 2.
Subjects visited the university at the start of each period, and
after 3 and 4 weeks of intervention. They received 4 tubs of mar-
garine at the start of each period, the amount needed for 4 weeks.
At the end of each week, the used margarine tubs had to be set
aside and returned to the department to be weighed to determine
compliance. Subjects completed a validated food frequency ques-
tionnaire (FFQ) at the end of all three intervention periods [17], and
a dietician checked these questionnaires to calculate energy and
nutrient intakes using the Dutch food composition table. Subjects
were asked not to change their habitual diet, level of physical ex-
ercise or use of alcohol throughout the three intervention periods
in the study.2.3. Blood sampling
Blood was sampled after an overnight fast. The same person
performed all venipuncture at approximately the same time of theTable 2







Sitosterol 0 64.8 1.4
Campesterol 0 38.1 2.4
Stigmasterol 0 29.6 0
Sitostanol 0 3.8 114.3
Campestanol 0 1.7 33.0
7a-OH-sitosterol 0.35 6.15 0.19
7a-OH-campesterol 0.09 2.48 0.08
7b-OH-sitosterol 0.80 11.39 0.51
7b-OH-campesterol 0.30 2.77 0.09
7-keto-sitosterol 1.67 5.41 2.31
7-keto-campesterol 1.67 5.54 2.23
a Plant sterol and stanol content in mg/mg and oxyphytosterol content in ng/mg.day. Blood was sampled at the start of each period and after 3 and 4
weeks of intervention. A clotting tube (Becton, Dickinson and
Company, Franklin Lakes, NY, USA) was sampled at each occasion
and serum was obtained by low-speed centrifugation at 1300  g
for 15 min at room temperature, at least half an hour after ven-
ipuncture. Serumwas stored at80 C and used for analysis of lipid
and (apo)lipoprotein concentrations, and for plant sterol and plant
stanol concentrations. An EDTA tube (Becton, Dickinson and Com-
pany, Franklin Lakes, NY, USA) was sampled at the start of each
period and after 4 weeks and plasma was obtained by low-speed
centrifugation at 1300  g for 15 min at 4 C, and then stored
at 80 C. To avoid auto-oxidation, oxyphytosterol concentrations
were determined in butylated hydroxytoluene (BHT)-enriched
plasma; for this 10 ml BHT (25 mg/mL ethanol) was added per 1 mL
of EDTA plasma, immediately after centrifugation.
2.4. Analyses
Total cholesterol (CHOD-PAP method; Roche Diagnostics, Man-
nheim, Germany), high-density lipoprotein cholesterol (HDL-C)
(CHOD-PAPmethod; RocheDiagnostics,Mannheim, Germany) after
precipitation of apoB-containing lipoproteinswith phosphotungstic
acid andmagnesium ions, and triacylglycerol (TAG) concentrations,
with correction for free glycerol, were analyzed in serum enzy-
matically (GPO-Trinder; SigmaeAldrich Corp., St. Louis, MO, USA).
All samples from one subject were analyzed within one run at the
end of the study. LDL-C concentrationswere calculated according to
the Friedewald equation [18]. Apolipoprotein concentrations (apoA-
1 and apoB100) were analyzed using highly sensitive immuno-
turbidimetric assays (Horiba ABX, Montpellier, France). Lipid and
(apo)lipoprotein concentrations fromweeks 3 and 4 were averaged
for data analysis. Plant sterol (sitosterol, campesterol), plant stanol
(sitostanol, campestanol), cholesterol precursor (lathosterol), cho-
lestanol and oxyphytosterol concentrations from week 4 were
analyzed by gaseliquid chromatographyemass spectroscopy (GCe
MS) as described previously [19,20]. Plant sterol, plant stanol and
lathosterol concentrationswere expressed as 102mmol/mmol total
cholesterol. The measured oxyphytosterols were 7a-hydroxy(OH)-
sitosterol, 7a-OH-campesterol, 7b-OH-sitosterol, 7b-OH-campes-
terol, 7-keto-sitosterol, and 7-keto-campesterol according the pro-
cedure as described by Husche et al. (20) and expressed as ng/mL.
Oxyphytosterol concentrations were standardized for cholesterol
concentrations and expressed as nmol/mmol cholesterol.
2.5. Statistics
To detect a change of 17 ng/mL in plasma oxyphytosterol con-
centrations with a power of 80% and a known within-subject var-
iation on the response of 34 ng/mL (20), a sample size of 47 subjects
was necessary, given an anticipated dropout rate of 10%. All data are
presented as means  standard deviations (SD). Effects of the
experimental products were evaluated by a univariate analysis of
variance (ANOVA) followed by Bonferroni’s correction for multiple
comparisons. Results were considered to be statistically signiﬁcant
if p < 0.05. Results were analyzed to assess whether gender effects
or carryover effects existed, and both effects were not present in the
data. All statistical analyses were performed using SPSS 18.0 for
Mac Os X (SPSS Inc., Chicago, IL, USA).
3. Results
3.1. Dietary intakes
As shown in Table 3, the average daily intakes of total energy
(MJ/day), protein (energy%), carbohydrates (CHO, energy%), total fat
Table 3







Energy (MJ) 10.6  3.4 10.6  3.2 10.5  3.2
Fat (energy%) 37.5  7.2 37.4  6.5 37.4  6.6
SAFAa 12.1  3.1 12.2  3.0 11.9  3.0
MUFA 14.4  3.2 14.6  2.7 14.6  3.0
PUFA 7.9  2.4 8.2  2.0 8.0  1.8
Protein (energy%) 15.5  3.6 15.4  3.4 15.4  3.2
CHO (energy%) 45.3  9.5 44.4  7.5 44.6  8.1
Alcohol (energy%) 2.9  2.9 2.6  2.6 2.8  3.2
Fiber (g/day) 23.5  7.8 24.0  7.5 23.3  7.6
Cholesterol (mg/day) 221  111 209  92 205  77
Vitamin E (mg/day) 13.1  5.3 13.6  5.8 13.3  5.7
Values are means SD. All subjects (n ¼ 43) received the three dietary conditions in
random order.
a SAFA: saturated fatty acids, MUFA: monounsaturated fatty acids, PUFA: poly-
unsaturated fatty acids, CHO: carbohydrates.
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unsaturated fatty acids (MUFA), and polyunsaturated fatty acids
(PUFA), energy%), ﬁber (g/day), cholesterol (mg/day) and vitamin E
(mg/day) did not differ between the three intervention periods.
3.2. Serum lipids and lipoproteins
Serum lipid and lipoprotein concentrations are shown in Table 4.
Compared with the control condition, serum total cholesterol
concentrations decreased by 0.30 0.51mmol/L (5.3%; p< 0.001)
in the sterol condition and by 0.29  0.42 mmol/L (5.3%;
p < 0.001) in the stanol condition. These reductions could almost
completely be ascribed to decreases in serum LDL-C concentrations.
In the sterol condition, serum LDL-C concentrations decreased by
0.29  0.43 mmol/L (8.1%) and in the stanol condition by
0.26  0.41 mmol/L (7.8%; p < 0.001 for both conditions). Serum
HDL-C concentrations were not different between the three con-
ditions. This shift towards a more beneﬁcial partitioning of cho-
lesterol was also reﬂected in the total cholesterol/HDL cholesterol
ratio, which decreased in the sterol condition by 0.14 0.36 (3.1%;
p < 0.05) and in the stanol condition by 0.18  0.35 (4.9%;
p< 0.01). Serum apolipoprotein B100 concentrations were reduced
in the sterol condition by 0.05  0.09 g/L (4.4%) and in the stanol
condition by 0.05  0.08 g/L (5.1%; p < 0.01 for both conditions).Table 4
Effect of consumption of plant sterol and plant stanol-enriched margarines on








Total cholesterol (mmol/L) 5.56  1.07 5.26  1.081 5.27  1.111
LDL cholesterol (mmol/L) 3.36  1.06 3.08  1.001 3.10  1.051
HDL cholesterol (mmol/L) 1.69  0.39 1.65  0.39 1.68  0.39
Total cholesterol/HDL 3.46  1.00 3.32  0.932 3.28  0.963
Triacylglycerol (mmol/L) 1.14  0.40 1.18  0.44 1.08  0.41
ApoB100 (g/L) 0.97  0.25 0.93  0.243 0.92  0.263
ApoA1 (g/L) 1.57  0.31 1.55  0.31 1.55  0.27
Sitosterol* 140  69 226  2553 88  354
Campesterol 214  83 346  1721 131  591,4
Sitostanol 4.3  3.3 5.5  5.7 22.4  11.71,4
Campestanol 2.8  1.6 3.5  2.0 13.1  7.71,4
Lathosterol 115  57 134  563 130  552
Cholestanol 165  0.33 153  322 155  322
Values are means  SD and *sterols are expressed as 102 mmol/mmol cholesterol.
All subjects (n ¼ 43) received the three dietary conditions in random order.
Signiﬁcantly different compared with control condition: 1(p < 0.001), 2(p < 0.05),
3(p < 0.01).
Signiﬁcantly different compared with sterol condition 4(p < 0.001).No differences were found in serum TAG and apolipoprotein A1
concentrations between the three conditions.
3.3. Serum plant sterols, plant stanols, lathosterol and cholestanol
Cholesterol-standardized serum plant sterol, plant stanol, lath-
osterol and cholestanol levels are shown in Table 4. Sitosterol levels
increased in the sterol condition by 86.6  199 102 mmol/mmol
cholesterol (49%; p < 0.01) compared with the control condition
and by 138  248 102 mmol/mmol cholesterol (167%; p < 0.001)
compared with the stanol condition. For campesterol, these values
were 132  137 102 mmol/mmol cholesterol (66%; p < 0.001) and
214  138 102 mmol/mmol cholesterol (179%; p < 0.001). In
addition, campesterol levels decreased in the stanol condition by
82.3  53.3 102 mmol/mmol cholesterol (37.3%) compared with
the control condition (p < 0.001).
Sitostanol levels increased in the stanol condition by 182  114
102 mmol/mmol cholesterol (511%; p < 0.001) compared with the
control condition and by 170  117 102 mmol/mmol cholesterol
(404%; p < 0.001) compared with the sterol condition. For cam-
pestanol, these values were 103  70 102 mmol/mmol cholesterol
(398%; p < 0.001) and 96  66 102 mmol/mmol cholesterol (295%;
p < 0.001). Lathosterol levels, a marker for cholesterol synthesis,
increased in the sterol condition by 189  454 102 mmol/mmol
cholesterol (24.1%; p < 0.01) and in the stanol condition by
147  322 102x mmol/mmol cholesterol (17.5%; p < 0.05) compared
with the control condition. Cholestanol levels, a marker for cho-
lesterol absorption, decreased in the sterol condition by 112  292
102 mmol/mmol cholesterol (5.2%; p < 0.05) and in the stanol
condition by 96 205102 mmol/mmol cholesterol (4.9%; p< 0.05)
compared with the control condition.
3.4. Plasma oxyphytosterols
Absolute oxyphytosterol concentrations (ng/mL) in BHT-
enriched EDTA plasma are shown in Table 5. 7b-OH-campesterol
concentrations were decreased in the stanol condition by
0.07  0.17 ng/mL (13.6%) compared with the control condition
(p < 0.01) and by 0.07  0.14 ng/mL (15.0%) compared with the
sterol condition (p < 0.01). Concentrations of the other oxy-
phytosterol were comparable between the three conditions.
Cholesterol-standardized oxyphytosterol levels (nmol/mmol
cholesterol) showed comparable results, i.e. a decreased 7b-OH-
campesterol level in the stanol condition compared with theTable 5








A 7a-OH-sitosterol 0.21  0.09 0.22  0.11 0.26  0.35
7a-OH-campesterol 0.09  0.05 0.09  0.06 0.08  0.05
7b-OH-sitosterol 1.17  0.35 1.09  0.52 1.09  0.58
7b-OH-campesterol 0.32  0.16 0.32  0.15 0.25  0.111,2
7-keto-sitosterol 2.49  0.58 2.35  0.78 2.35  0.60
7-keto-campesterol 0.48  0.19 0.49  0.28 0.44  0.22
B 7a-OH-sitosterol 0.10  0.05 0.11  0.06 0.12  0.16
7a-OH-campesterol 0.04  0.03 0.05  0.03 0.04  0.02
7b-OH-sitosterol 0.54  0.17 0.56  0.26 0.50  0.26
7b-OH-campesterol 0.15  0.08 0.17  0.08 0.12  0.051,3
7-keto-sitosterol 1.18  0.34 1.22  0.45 1.10  0.30
7-keto-campesterol 0.23  0.10 0.26  0.15 0.21  0.104
Panel A: Values are means  SD and are expressed as ng/mL. Panel B: Values are
means  SD and are expressed as nmol/mmol cholesterol. All subjects (n ¼ 43)
received the three dietary conditions in random order.
Signiﬁcantly different compared with sterol condition 1(p < 0.01), 4(p < 0.05).
Signiﬁcantly different compared with control condition 2(p < 0.01), 3(p < 0.05).
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addition, the 7-keto-campesterol level was reduced in the stanol
condition compared with the sterol condition (p < 0.05).
4. Discussion
There is an ongoing debate whether there is a relation between
circulating serum plant sterol concentrations and cardiovascular
risk. Based on ﬁndings from animal studies [21e23], we hypothe-
sized that plant sterols themselves are not, but become athero-
genic, when oxidized. We here show that in healthy volunteers,
despite the increase in non-oxidized plant sterols concentrations,
absolute concentrations of oxyphytosterols do not increase after
consumption of plant sterol-enriched margarines. However, plant
stanol consumption reduced 7b-OH-campesterol concentrations
and e when standardized for cholesterol also 7-keto-campesterol
levels e compared with the control as well as with the plant sterol-
enriched margarine.
Oxyphytosterol concentrations in humans have only been
determined in a few e merely cross-sectional e studies. In 2001,
Plat et al. identiﬁed oxyphytosterols in serum of phytosterolemic
patients, but not in serum of healthy subjects [15]. A few years later,
Grandgirard et al. used a method with a lower detection limit and
detected a- and b-epoxysitosterol, 7-keto-sitosterol and sitosta-
netriol in plasma of healthy subjects in a range of 5e57 ng/mL [24].
We found oxyphytosterol concentrations in a range of 0.08e
2.49 ng/mL, but measured different oxyphytosterols. 7-keto-sitos-
terol, however, was measured in both studies and while we
measured a mean concentration of 2.5 ng/mL, Grandgirard et al.
found a mean concentration of 6.1 ng/mL. The amount BHT added
to the samples differed between our and Grandgirard’s study (1%
vs. 0.05%), whichmight explain the discrepancies in oxyphytosterol
concentrations. Menéndez-Carreño measured the same oxy-
phytosterols as we did, but found somewhat higher oxyphytosterol
concentrations in serum of healthy volunteers (0.25e4.48 ng/mL)
[25]. This difference between our results with Menéndez-Carre-
ño’s data is probably due to the use of different methods, empha-
sizing the need for standardization of oxyphytosterol analyses.
Recently, Husche et al. determined oxyphytosterol concentrations
in plasma from 16 volunteers, who were given a plant sterol-
enriched margarine for 4 weeks, providing 3.0 g of plant sterols
per day. Oxyphytosterol concentrations did not change after plant
sterol consumption, except for an 85% increase in 7b-OH-sitosterol
concentrations [20]. In our study 7b-OH-sitosterol concentrations
did not change after consumption of a plant sterol-enriched mar-
garine, despite the fact that baseline 7b-OH-sitosterol concentra-
tions were comparable between the two studies (1.20 0.54 ng/mL
vs. 1.17  0.35 ng/mL). The study of Husche et al., however, was not
placebo-controlled, which might have inﬂuenced the results. The
range of the different oxyphytosterol concentrations in Husche’s
study and our study was comparable (0.07e3.01 ng/mL vs. 0.08e
2.49 ng/mL) and this consistency in baseline oxyphytosterol con-
centrations may help to deﬁne normal serum values.
So far oxyphytosterol concentrations have been reported as
absolute values in literature. The question arises whether concen-
trations, as for non-oxidized plant sterols, should be standardized
for cholesterol concentrations or not. Plant sterols concentrations
are standardized for cholesterol, as plant sterols are transported by
lipoproteins. This may be true for oxyphytosterols as well. When
oxyphytosterols are standardized for cholesterol concentrations,
conclusions were very comparable to those of the absolute changes,
i.e. there was a signiﬁcant decrease in 7b-OH-campesterol con-
centration in the stanol condition compared to the sterol and
control condition. In addition, 7-keto-campesterol was signiﬁcantly
decreased in the stanol compared with the sterol condition.Alternatively, oxyphytosterols levels can also be expressed as the
proportion of circulating plant sterol concentrations, which more
or less indicates the percentage of substrate that is oxidized. The
percentage oxidized plant sterols of total plant sterols is the highest
in the stanol condition and the lowest in the sterol condition, but
this is mostly due to a change in plant sterol concentrations and not
in oxyphytosterol concentrations. For this reason, it was chosen to
only express oxyphytosterols in absolute and cholesterol-
standardized levels (Table 5).
Theoretically, oxyphytosterols can be derived from absorption of
oxidized plant sterols present in food, as well as from endogenous
synthesis (either from enzymatic or non-enzymatic ring-oxidation
processes). Since this study cannot distinguish between endoge-
nously formed and diet-derived oxyphytosterols, we can only
speculate about the origin of the measured circulating oxy-
phytosterols. Althoughphytosterolemic patients followa strict plant
sterol-poor (and consequently also oxyphytosterol poor) diet, they
still have elevated plasma (oxy)phytosterol concentrations [4]. This
could indicate that plasma oxyphytosterols originate from in vivo
oxidation of the high circulating non-oxidized serum plant sterol
concentrations. A second potential indication for the in vivo for-
mation of oxyphytosterols might be found in the oxyphytosterol
content of the margarines. Oxyphytosterols in the diet are mainly
derived from plant sterol-enriched products [16]. Our plant sterol-
enriched margarine contained w34 ng oxyphytosterols per milli-
grammargarine, while the oxyphytosterol content of the other two
margarines was w5 ng/mg margarine (Table 2). However, this
higher oxyphytosterol content did not translate into increased
serum concentrations, which might suggest that serum concentra-
tions are not related to absorption of oxyphytosterols from the diet.
On the other hand, while non-oxidized plant sterol concentrations
increased, oxyphytosterol concentrations did not increase, which
could imply that oxyphytosterols are not formed in vivo but origin
from intestinal absorption. In this respect, the relative absorption of
different oxyphytosterols might give more insight into the origin of
circulating oxyphytosterols. The sterol-enriched margarines con-
tained twice as much sitosterol oxidation products as campesterol
oxidation products, while concentrations of sitosterol oxidation
products in plasma were four to ﬁve times as high as campesterol
concentration products. This may suggest that sitosterol oxidation
products are preferentially absorbed or formed in vivo. However, in
humans, non-oxidized campesterol is better absorbed than non-
oxidized sitosterol and serum concentrations are also higher [26].
Human data is lacking, but animal studies have consistently shown
that e analog to the non-oxidized sterols e campesterol oxidation
products are better absorbed than sitosterol oxidation products
[27,28]. This may suggest that in vivo formation of plant sterol oxi-
dationproducts ismore likely than intestinal absorption, or perhaps
that excretion of sitosterol oxidation products is low. To deﬁnitively
answer the question whether plasma oxyphytosterols result from
absorption or from in vivo formation, future studies should be per-
formed inwhich for example labeled non-oxidized plant sterols are
consumed and subsequent enrichment in labeled plasma oxy-
phytosterols is measured. In addition, little is known about tissue
distribution of oxyphytosterols and whether serum oxyphytosterol
concentrations relate to tissue concentrations. These questions
should be addressed in future studies to elucidate the physiological
role of circulating oxyphytosterols in humans.
We observed a decrease in absolute 7b-OH-campesterol con-
centrations or cholesterol-standardized 7b-OH-campesterol and 7-
keto-campesterol after plant stanol-enriched margarine con-
sumption. Again, it is not known whether this is due to effects on
in vivo formation or on absorption. Also, it may be a chance ﬁnding.
However, if true, it is interesting that 7b-OH-cholesterol (choles-
terol oxidation product) is regarded as the most atherogenic
S. Baumgartner et al. / Atherosclerosis 227 (2013) 414e419 419oxysterol and has been identiﬁed as the strongest predictor of
a rapid progression of carotid atherosclerosis in humans [29].
Whether 7b-OH-campesterol might also be regarded as an athe-
rogenic compound remains to be determined.
Potential differences in dietary oxyphytosterol intake between
treatments cannot be eliminated as the study is performed in
a free-living setting, but due to the cross-over design and low
oxyphytosterol content in daily diet this is not very likely.
In conclusion, we have shown that a daily consumption of
a plant sterol-enriched margarine for a period of 4 weeks does not
increase plasma oxyphytosterol levels. We further found that plant
stanol consumption reduced the absolute and cholesterol-
standardized 7b-OH-campesterol levels and the cholesterol-
standardized 7-keto-campesterol level. The reproducibility and
possible clinical implication of these reductions remain to be
determined and deserve further investigation.
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